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Arterial reconstructions with vein grafts fail more frequently than with arterial grafts. One of the 
causes of graft failure is damage due to overstretching of the graft wall. Overstretching is caused 
because the vein graft, which has a poorly developed medium, cannot withstand the arterial blood 
pressures. The aim of this study is to evaluate whether damage due to overstretching can be 
prevented and a gradual adaptation of the vein graft to the arterial blood pressures can be induced by 
applying a microporous, elastomeric, degradable prosthesis around the vein graft. Therefore, autolo- 
gous vein grafts (length l.Ocm) with and without supporting prostheses (composite vein grafts and 
control vein grafts, respectively) were interposed into both carotid arteries of rabbits. Microporous, 
elastomeric, biofragmentable polyurethane-based prostheses and microporous, elastomeric, 
biodegradable prostheses made of poly-i:-caprolactone or a copolymer of rxaprolactone and 3.6- 
dimethyl-1,4-morpholine-2,Sdione with a monomer ratio of 95.5:4.5 were prepared. The grafts were 
evaluated up to 6wk after implantation. The control vein grafts showed severe destructive changes 
such as de-endothelialization, dlsruption of the media with oedema, degradation of the elastic laminae 
and infiltration of polymorphonuclear leucocytes into the vein graft wall, leading eventually to a fibrotic 
wall. In contrast, the composite vein grafts showed a preservation of the smooth muscle cell layers 
and the elastic laminae with only few polymorphonuclear leucocytes infiltrated into the vein graft wall. 
Moreover, the wall of the vein graft gradually increased in thickness by the formation of regular 
circularly oriented cellular layers beneath the original longitudinally oriented smooth muscle cell 
layers, indicating a gradual adaptation of the vein graft to the arterial conditions. It appeared that the 
arterialization rate depended on the degradation rate of the supporting prostheses. Microporous 
prostheses made of a copolymer of x-caprolactone and 3,6-dimethyl-1,4-morpholine-2,5-dione with a 
monomer ratio higher than 95.5.4.5 are recommended to support the vein grafts. 
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Arterial autografts are the ideal material for the 
reconstruction of malfunctioning small diameter 
arteries’. After implantation, the graft remains viable 
and possesses properties like those of a normal artery, 
such as compliance, flexibility and antithrombogeii- 
city. Its applicability, however, is limited because 
grafts of the required length and diameter are not 
always sufficiently available. Moreover, harvesting of 
these grafts may occasionally lead to tissue necrosis at 
the donor sites. These limitations of arterial autografts 
are not or to a lesser extent encountered with the 
application of venous autografts which are therefore 
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still frequentlv used as grafts for the rc?c:onstruc:tiorl ol 
malfunctioning small diameter arteries”..‘. The 
drawback of this type of graft is its relatively poor graft 
performance. For example, applied for coronary 
bypass procedures, the cumulative patency rate in 5 yr 
for arterial autografts is 93% and for vein grafts ~5’31~. 
Several investigators have observed that after implaIi- 
tation the vein grafts are damaged, showing de- 
endothelialization, disruption of the medial layers and 
the development of an inflammatory reaction”. Later 
changes include artherosclerosis, dilation, ancurvsm 
formation and subintimal thickening, which rnal: 
ultimately lead to graft failure”..‘, ‘,-!‘. It has bee;l 
proposed that damage to the vein graft is caused bv 
surgical manipulations during transplant;ltion”““. 
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Therefore, improved handling procedures were 
developed which indeed resulted in a better graft 
performancel’. 12,14,15,17, However, other factors which 
are inherent to the transplantation procedure leading 
to damage of the vein graft are ischaemia due to the 
interruption of the vasa vasorum and overstretching of 
the vein graft wall due to the arterial blood 
pressure13’18-20. Overstretching is caused because the 
vein graft has a poorly developed medium with few 
smooth muscle cell layers which is not adapted to the 
relatively high arterial pressures. Overstretching may 
lead to a loss of the integrity of the graft wall and 
ultimately to graft failure. Therefore, it is expected that 
if overstretching is prevented, the graft performance 
will be improved. This was confirmed by Barra et al.‘l 
and Karayannacos et al.“, who have shown that a 
constrictive Dacron mesh applied around the vein graft 
reduces the degree of deterioration of the vein wall. 
The long-term fate of these composite vein grafts, 
however, might be less successful. These prostheses 
are non-compliant, which might induce intimal 
hyperplasia formation at the anastomotic sidesz3. 
Furthermore, the prostheses are non-resorbable, which 
might cause perigraft fibrosisz4 and ultimately constric- 
tion of the grafts. 
The aim of this study was to evaluate whether 
damage due to overstretching can be prevented and a 
gradual adaptation of the vein graft to the arterial 
blood pressures can be induced by applying a 
microporous, elastomeric, degradable prosthesis 
around the vein graft. Therefore, autologous vein grafts 
(length l.Ocm) with and without supporting prosthe- 
ses (composite vein graft and control vein graft, respec- 
tively) were interposed into both carotid arteries of 
rabbits and evaluated up to 6 wk after implantation. To 
study the effects of degradation of the prostheses on 
the arterialization process, different compositions of 
prostheses with different degradation rates were tested. 
A discussion will be given on the suitability of several 
types of polymer systems for this application. 
MATERIALS AND METHODS 
Materials 
Polyetherurethane Estane ” 5714fl (PEU; Goodrich, 
Leidschendam, The Netherlands) was purified by 
precipitation of a 10 wt% solution in N,N-dimethylfor- 
mamide (DMF) into water. Poly-c-caprolactone (PCl; 
Interox Chemical Ltd, ~a~ington, UK] and poly(~- 
lactide) (PLLA; TNO, Delft, The Netherlands) were 
purified by precipitation of 10 wt% solutions in chloro- 
form (CHCIS) into methanol. A copolymer of s-caprolac- 
tone and 3,6-dimethyl-1,4-morpholine-2,5-dione 
(monomer ratio 95.5:4.5; Cop 4.5) was synthesized as 
described by in’t Veld et d2’. The intrinsic viscosities 
of solutions of PLLA in CHCl, and of PC1 and Cop 4.5 
in tetrahydrofuran (THF), as determined with an 
Ubbelohde viscometer at 25”C, were 2.60, 0.63 and 
0.82 dl/g, respectively. 
Fractions of sodium citrate (Janssen, Beerse, Belgium) 
differing in particle size were obtained as follows. A 
saturated solution of sodium citrate in a 1:2 (v/v) 
mixture of methanol and water was cooled from 70 to 
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4°C to induce crystallization of sodium citrate. 
Subsequently, the formed crystals were filtered, rinsed 
with ethanol and then dried. Sodium citrate thus 
obtained was fractionated with Tamson test sieves 
(Zoetermeer, The Netherlands) with mesh sizes of 38, 
63 and 106pm to obtain crystals with the following 
sizes: smaller than 38jtm, 38-63 pm and 63-106 pm, 
respectively. 
Methanol, ethanol, DMF, THF, dimethylsulphoxide 
(DMSO) and CHCls (all Merck, Darmstadt, Germany) 
were of synthesis or analytical grade and were used 
without further purification. 
Fabrication and characterization of the 
prostheses 
Prostheses composed of PEU-PLLA (9O:lO wt”h) and 
PEU-PC1 (9O:lO wt%) were prepared by means of a 
repeated immersion precipitation/salt casting techni- 
que 26*27. A glass rod (diameter 2.5mm) was dipped 
into a suspension of a polymer solution and sodium 
citrate particles at ambient temperature. Subsequently, 
the glass rod on which a layer of the suspension was 
deposited was placed for 5 s into ethanol-water (90~10 
wt%) and therea~er for 10 min into ethanol-water 
(5050 wt%), also at ambient temperature to induce 
polymer precipitation. Thereafter the precipitated 
polymer was exposed to air until nearly dry and the 
next layer was deposited on top of the first one by 
means of the same procedure. This procedure was 
continued until five layers were deposited. Then the 
prostheses were thoroughly rinsed in water and 
ethanol to dissolve the salt particles and to extract the 
solvent residues, and subsequently stored in ethanol. 
The composition of the suspension used for the 
preparation of the first four layers was PEU-PLLA- 
DMF-THF-~HCl~-sodium citrate (particle size 
<38pm) (4.5:0.5:44.0:12.0:28.4:10.6 wt%) or PEU-PCl- 
DMF-THF-sodium citrate (particle size ~38 pm) 
(5.4:0.6:69.0:12.1:12.9 wt%) and for the last layer 
PEW-PLLA-DMF-THF-CHCI,-sodium citrate (particle 
size 68-106 pm) (3.4:0.3:38.0:4.8:23.0:30.5 wt%) or 
PEU-Pal-DMF-THF-sodium citrate (particle size 68- 
106pm) (4.5:0.5:49.1:8.7:37.2 wt%). 
Prostheses composed of PC1 were prepared by means 
of a two-step thermally induced phase separation/salt 
casting techniquez7. These prostheses were also 
prepared by depositing a number of layers onto a glass 
rod (diameter 2.5 mm) by means of dip coating. In this 
case, polymer precipitation was induced by cooling a 
suspension of a polymer solution and sodium citrate 
particles. After the glass rod was dipped into the 
suspension at 6O”C, the glass rod containing a layer of 
the suspension was cooled to ambient temperature for 
15 min. Subsequently, the prostheses were placed into 
water~thanol (25:75 wt%) for 15 min, also at ambient 
temperature, to partially extract the solvent. The 
prostheses were then exposed to air until nearly dry 
and the second layer was deposited by means of the 
same procedure. After two layers had been deposited, 
the prostheses were treated like the PEU-based prosthe- 
ses. The composition of the suspension used for the 
preparation of the first layer was PCl-DMS~sodium 
citrate (particle size <38,itm) (10:57.3:32.7 wt%) and 
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for the second layer PCl-DMSO-sodium citrate 
(particle size 38-63 pm) (6.7:53.3:40.0 wt%). 
Prostheses composed of Cop 4.5 were prepared by 
means of a repeated evaporation precipitation/salt 
casting technique2”. These prostheses were prepared 
by means of a similar procedure as used for the 
preparation of the PEU-based prostheses except that 
the method of polymer precipitation was changed. 
Instead of immersing a suspension of a polymer 
solution and sodium citrate particles into a non- 
solvent, polymer precipitation was induced by 
allowing the solvent to evaporate by air exposure for 5 
min at ambient temperature after the deposition of 
each layer. In total, seven layers were deposited onto 
the glass rod (diameter 2.5 mm). The composition of 
the suspension used for the preparation of the first six 
layers was Cop 4.5-CHCl,-sodium citrate (particle size 
<38/irn) (4.7:77.9:17.4 wt%) and for the last layer Cop 
4.5-CHCl,-sodium citrate (particle size 68-106 pm) 
(2.2:80.6:17.2 wt%). 
The porous structures of the prostheses were 
evaluated by means of scanning electron microscopy 
(SEM). Therefore, the prostheses were coated with a 
layer of gold with a Balzer sputter unit and examined 
with a Jeol JSM 35 scanning electron microscope 
operating at 15 kV. 
The mechanical properties of the prostheses were 
evaluated by means of stress-strain measurements. 
The prostheses were wetted with distilled water and 
subsequently fixed between the clamps of an Instron 
tensile tester (Floor model TT-CM). The prostheses 
(n = 3), with a length of 1 cm, were drawn in the 
longitudinal direction with a speed of 0.5 cm/min at 
25 ‘C until breakage. 
Implantation 
Both left and right carotid arteries of male Chinchilla 
rabbits weighing 3.0-3.5 kg were used to evaluate 
composite vein grafts consisting of autologous veins 
surrounded by prostheses. The site of implantation 
(left or right carotid artery) was randomized. Micropor- 
ous prostheses composed of PEU-PLLA (9O:lO wt%), 
PEU-PC1 (9O:lO wt%), Cop 4.5 and PC1 were used. The 
prostheses were sterilized by ethylene oxide (PEU- 
based prostheses) or by ethanol (Cop 4.5 and PC1 
prostheses). After the rabbit was anaesthesized by 
intravenous injection of sodium pentobarbitone 
(Nembutol, 30mg/kg) and intubated with 1% 
halothane (Fluothane), the carotid arteries and the 
jugular veins were carefully exposed by making a 
ventral midline incision in the neck under sterile 
conditions. One centimetre segments of the jugular 
veins were harvested and interposed into the carotid 
arteries with end to end anastomoses. The vein grafts 
were implanted by means of microsurgical techniques, 
as described before”‘. The vein grafts with supporting 
prostheses were implanted as shown schematically in 
Figure Z. The prostheses had a length of 1.5 cm and 
overlapped both anastomoses. Both types of graft were 
anastomosed to the carotid arteries with interrupted 
sutures (Ethilon 9-0, BV-4 needle, Ethicon). Vein grafts 
matching the diameter of the carotid artery (2.5 mm) 
and oversized vein grafts (3.5 mm) were used for the 
Figure 1 Schematic drawing of the implantation of the 
composite vein graft. 
Table 1 In viva experiments 
lmplantatlon time 
1 wk 3wk 6wk 
Control n 6 n 6 n-a 
PEU-PCI (9:l) n :~ 6 n -6 n=7 
PEU-PLLA (9:l) n-6 n-6 n-a 
PCI n-2 n =2 n-4 
cop 4.5 n: 6 n-6 n=a 
control and composite grafts, respectively. The grafts 
were harvested at different time intervals (see ?‘nble Z) 
and prepared for SEM and light microscopy (LM) by 
means of standard procedures”“.““. The wall thickness 
and the inner diameter of the explanted vein grafts and 
the carotid artery were determined as described 
before”“. The data were mutually compared by means 
of the Mann-Whitney test. The data were considered 
to be significantly different when P < 0.05. 
RESULTS 
Characteristics of the prostheses 
For the characteristics of the prostheses, see Tnhle 2. 
Two different pore structures were obtained (see 
Figurt! 2): sponge-like structures with highly intercon- 
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Table 2 Characteristics of the prostheses 
Composition 
prostheses 
Wall 
thickness 
(mm) 
Internal 
diameter 
(mm) 
Pore size* 
(pm) 
Wall density Weight/ Strain at Force at 
(mg/mm3) length breakage & breakage f 
(mglmm) s.d. (%) s.d. (N) 
PEU-PCI (9:l) 0.40 2.5 30-l 00 0.26 1.13 >400 >2.0 
PEU-PLLA (9:l) 0.35 2.5 30-l 00 0.36 0.95 >400 >1.5 
PCI 0.90 2.5 75-l 50 0.14 1.30 80 * 9 2.9 i- 0.3 
cop 4.5 0.70 2.5 30-l 00 0.26 1.83 100 + 12 3.7 It 0.4 
‘Pore size inner side-outer side 
netted pores (PEU-based and PC1 prostheses) and leafy 
structures with poorly interconnected pores (Cop 4.5 
prostheses). With the preparation of the PEU-based 
and PC1 prostheses, pores were formed by two differ- 
ent mechanisms. Pores in these prostheses were 
formed by the entrapment of sodium citrate particles 
in the polymer matrix during precipitation and the 
subsequent extraction of the sodium citrate particles 
and by demixing processes occurring during precipita- 
tionz7. Both pore-forming mechanisms resulted in the 
formation of sponge-like structures with highly 
interconnected pores. With the preparation of the Cop 
4.5 prostheses, pores were only formed by the entrap- 
ment of sodium citrate particles in the polymer matrix 
during precipitation and the subsequent extraction of 
the sodium citrate particlesz7. Therefore, these prosthe- 
ses had a different pore morphology. The prostheses 
showed a leafy structure with a relatively poor 
interconnectivity of the pores. 
All four types of prosthesis showed elastomeric 
behaviour at 25°C (see Figure 3). However, the elasto- 
meric properties of the PC1 and Cop 4.5 prostheses as 
expressed in the values for the strain at breakage were 
not as good as those of the PEU-based prostheses. 
Furthermore, the PC1 and Cop 4.5 prostheses had 
higher initial moduli than the PEU-based prostheses. 
These differences can be ascribed to differences in 
specific characteristics of the materials from which the 
prostheses were made, as well as to differences in 
weight per length of the prostheses. 
In viva experiments 
Control grafts 
One week implants: the inner surfaces of the control 
vein grafts were denuded from endothelium for 50%. 
The graft wall had an edematous appearance and was 
infiltrated by many polymorphonuclear leucocytes. 
Furthermore, the smooth muscle layers were comp- 
letely disrupted and showed only fragments of the 
elastic laminae (see Figure 4a). 
Three week implants: the endothelium was fully 
recovered and the edema had disappeared. Irregular 
proliferated cells, most likely mature fibroblastszg, had 
partially replaced the areas of inflammation, while the 
elastic laminae could no longer be observed. 
Six week implants: irregular proliferated mature 
fibroblasts had completely replaced the areas of inflam- 
mation (see Figure 4b). 
Composite grafts 
One week implants: the inner surface of the composite 
vein grafts were denuded from endothelium for 20% 
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Figure 2 SEM micrographs of the prostheses. a, PEU- 
PLLA prosthesis. b, PCI prosthesis. c, Cop 4.5 prosthesis 
(the PEU-PCI prosthesis had a similar appearance to the 
PEU-PLLA prosthesis). 
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only. The graft wall showed no edema and only few 
polymorphonuclear leucocytes had infiltrated. The 
smooth muscle cell layers, including the elastic 
laminae, were hardly affected. No major histological 
differences were observed between the four types of 
2 
composite vein grafts (see Figure 4~). The inner 
diameter of all vein grafts was equal to that of the 
adjacent artery (see Table 3). The wall thickness of the 
vein grafts was the same in all cases, but smaller than 
that of the adjacent artery (see Tnble 4). None of the 
prostheses showed signs of fragmentation. Further- 
more, the prostheses showed limited perigraft tissue 
0 100 200 ingrowth. 
Strain (%) 
Three week implants: the endothelium was fully 
recovered and infiltrated polymorphonuclear 
Figure 3 Examples of force-strain curves of: a, the PEU- leucocytes could no longer be observed. The vein 
PCI prothesis; b, the PEU-PLLA prosthesis; c, the PCI grafts supported by the Cop 4.5 prostheses were 
prosthesis; and d, the Cop 4.5 prosthesis. dilated as compared to the adjacent artery. In all other 
Figure 4 Light micrographs of the vein grafts. a, Control vein graft 1 wk after implantation showing disrupted smooth muscle 
cell layers and infiltrated polymorphonuclear leucocytes (see arrows). b, Control vein graft 6wk after implantation showing 
irregular proliferation of mature fibroblasts. c, Composite vein graft (PEU-PCI prosthesis) 1 wk after implantation showing 
preserved smooth muscle cell layers and hardly any infiltrated polymorphonuciear leucocytes. d, Composite vein graft 
(PEU-PCI prosthesis) 6wk after implantation showing an increased thickness of the vein graft wall and several layers of 
circularfy oriented immature fibroblasts (asterisks) underneath the original longitudinally oriented smooth muscle cell 
layers. V, vein wall; P, prosthesis. Magnification x250. 
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Table 3 Inner diameter of the implants 
Graft Inner diameter (mm) 
1 wk 3 wk 6 wk 
implants implants implants 
PEU-PCI 1.04 * 0.13 1.06 f 0.13 1.11 f 0.13 
PEU-PLLA 1.00 zt 0.11 1.08 zt 0.17 1.11 f 0.14 
PCI nd nd nd 
cop 4.5 1.08 5 0.13 1.54 * 0.07* 1.47 zt 0.18+ 
Carotid artery - - 1.05 * 0.13 
‘Significantly different from the inner diameter of the carotid artery and the 
vein grafts supported by the PEU-PCI and the PEU-PLLA prostheses 3wk 
after implantation (P < 0.01). 
‘Significantly different from the inner diameter of the carotid artery and the 
vein grafts supported by the PEU-PCI and PEU-PLLA prostheses 6 wk after 
implantation (P < 0.01) 
Values are given as mean f s.d. nd. no dilation (not measured). 
Table 4 Wall thickness (intima and media) of the implants 
Graft Wall thickness (,um) 
1 wk 3 wk 6 wk 
implants implants implants 
PEU-PCI 
PEU-PLLA 
PCI 
cop 4.5 
63 I!= 21 121 * 25 125 i 32* 
67 I!= 20 138 * 56 194 * 29 
F* 13 :4m2 * 38 
nm 
163 f 30+ 
Carotid artery - - 206 f 22 
*Significantly different from the wall thickness of the carotid artery and the 
vein grafts supported by the PEU-PLLA prostheses 6wk after implantation 
(P < 0.01). 
+Slgnificantly different from the wall thickness of the carotid artery (P < 0.05). 
Values are given as mean * s.d. nm. not measured. 
grafts the inner diameter was equal to that of the 
adjacent artery (see Table 3). In all cases the wall of 
the vein grafts was increased in thickness as compared 
to the 1 wk implants but was still thinner than that of 
the adjacent artery (see Table 4). The wall thickness 
was increased by the development of regular layers of 
circularly oriented cells, most likely young and 
immature fibroblasts, beneath the well preserved 
smooth muscle cell layers’“. The Cop 4.5 prostheses 
were degraded excessively: only fragments of the 
prosthetic material were left. The PEU-PLLA prosthe- 
ses were also fragmented, although less excessively 
than the Cop 4.5 prostheses. The PEU-PC1 and PC1 
prostheses did not show signs of fragmentation. The 
Cop 4.5 prostheses showed infiltration of many 
capillaries and multinuclear giant cells over the whole 
thickness of the prosthetic wall. The same picture was 
seen in both PEU-based prostheses, whereas only very 
limited perigraft tissue ingrowth was observed in the 
PC1 prostheses. 
Six week implants: the vein grafts supported by the 
Cop 4.5 prostheses did not show a further dilation. 
In all other cases the inner diameter of the vein grafts 
still equalled that of the adjacent artery (see Table 3). 
The wall of the dilated vein grafts supported by the 
Cop 4.5 prostheses was further thickened as compared 
to the 3 wk implants but was still thinner than that of 
the adjacent artery. The wall thickness of the vein 
grafts supported by the PEU-PLLA prostheses had 
reached that of the adjacent artery, whereas those of 
the vein grafts supported by the PEU-PC1 prostheses 
(see Figure 4d) were still thinner than that of the 
adjacent artery (see Table 4). No remnants of the Cop 
4.5 prostheses could now be observed. The PEU-PLLA 
prostheses had fallen apart into fragments. The PEU- 
PC1 prostheses were also fragmented, although less 
excessively than the PEU-PLLA prostheses. The PC1 
prostheses still seemed unaffected. The Cop 4.5, PEU- 
PLLA and PEU-PC1 prostheses showed the infiltration 
of many capillaries and multinuclear giant cells over 
the whole thickness of the prosthetic wall. The PC1 
prostheses showed only limited perigraft tissue 
ingrowth. 
Wrinkling or folding of the vein grafts was never 
observed during the 6 wk of implantation. 
DISCUSSION 
Our results clearly demonstrate that the arterialization 
of autologous vein grafts used for the reconstruction of 
small diameter arteries is improved when a micropor- 
ous, elastomeric and degradable prosthesis supports 
the vein graft. The results particularly demonstrate 
that the vein grafts adapt gradually and regularly to the 
arterial conditions when the degradation of the prosthe- 
ses is in step with the biological regeneration process. 
After implantation, the control grafts showed severe 
destructive changes including de-endothelialization, 
complete disruption of the smooth muscle layers with 
edema, disintegration of the elastic laminae and an 
inflammatory reaction. 
In contrast, the prostheses used to support the vein 
grafts reduced these destructive changes and 
prevented an inflammatory reaction in the wall. The 
severe destructive changes observed in the control 
vein grafts can therefore only be ascribed to the disten- 
sion by the arterial pressures and pulsatile blood flow. 
We used oversized vein grafts in the prostheses to 
ensure that overstretching could not occur. Therefore, 
the minor damage still observed might be ascribed to 
the handling procedures during transplantation and 
ischaemia. In time, the wall of the vein grafts gradually 
increased in thickness by the formation of regular 
circularly oriented cellular layers beneath the original 
longitudinally oriented smooth muscle cell layers, 
indicating a regular adaptation of the vein wall to the 
arterial blood pressures and pulsatile blood flow, i.e. 
arterialization. These circularly oriented cellular layers 
consisted of young and immature fibroblastszg, which 
have the potential to transform into smooth muscle 
cells. Because the fibroblast layers formed highly 
organized structures, this transformation is likely to 
occur or had already been started. However, long-term 
in viva experiments are required to investigate whether 
under these conditions the fibroblasts are indeed 
transformed into smooth muscle cells and a medium 
resembling that of an artery of normal architecture and 
function develops. In contrast, the control vein grafts 
showed no regularly and circularly oriented cellular 
layers at 6wk and because of the mature aspect of 
fibroblasts, a transformation of the fibroblasts into 
smooth muscle cells is not likely. 
According to Zwolak et a1.3’, vein grafts adapt to the 
arterial conditions by a thickening of their wall. This 
thickening proceeds until the ratio of the inner 
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diameter and the wall thickness has reached the same 
value as that of the adjacent artery. Cell stretching 
induces cell proliferation and stimulates cells to 
produce and to release extracellular matrix 
components”“~““. Adaptation of the vein graft to the 
arterial conditions by thickening of the wall can be 
ascribed to these biological processes. However, when 
unsupported vein grafts are used, thickening of the 
vein wall is accompanied by an increase of the inner 
diameter’l. Dilation of the unsupported vein grafts 
beyond the diameter of the artery can be prevented by 
using smaller diameter veins. However, damage in the 
vein wall due to overstretching remains. 
The arterialization process of the vein grafts 
supported by the prostheses can be explained by the 
following mechanism. Immediately after implantation, 
graft dilation is prevented by the presence of a support- 
ing prosthesis around the vein graft. In time, the 
prosthesis degrades and its supporting function is 
gradually lost. This gradual loss of the support 
combined with the elastomeric properties of the 
prostheses results in a slow increased stretching of the 
vein graft wall without damage caused by acute 
overstretching. As a consequence, cell proliferation 
and the production and release of extracellular matrix 
components are slowly induced, resulting in a thicken- 
ing of the vein graft wall, by which the increased 
stretching is counteracted. Because the loss of support 
is a gradual process, adaptation of the vein graft to the 
arterial conditions proceeds in a gradual way. Since 
disruption of cellular layers and the inflammatory 
reaction are prevented, the structure of the vein wall 
regenerates normally and shows no degeneration into 
fibrosis like the acutely overstretched unsupported 
vein grafts. The process of vein wall thickening 
proceeds until the ratio of the inner diameter and the 
wall thickness has reached the same value as that of 
the adjacent artery. By that time the vein graft has 
acquired sufficient strength to withstand the arterial 
blood pressures and the pulsatile blood flow. When 
the supporting prosthesis degrades very rapidly, the 
loss of support may be too rapid. In this case, thicken- 
ing of the vein graft wall cannot keep pace with the 
loss of support of the prosthesis. This process was 
observed with the vein grafts supported by the Cop 4.5 
prostheses. Already, within 3wk of implantation, the 
Cop 4.5 prostheses had degraded excessively. At this 
time the vein graft was dilated as compared to the 
adjacent artery. Although the wall thickness had 
increased after 6 wk of implantation, the ratio of the 
inner diameter and the wall thickness of the vein graft 
had not vet reached the same value as that of the 
adjacent artery. Therefore, it is expected that in time 
the wall thickness will increase in size. The PEU- 
PLLA prostheses were fragmented excessively after 
6 wk of implantation and had most likely lost their 
supporting fimction completely”. At that time the 
vein wall had already reached the same thickness as 
that of the adjacent artery and graft dilation was not 
observed. Therefore, we may conclude that the rate of 
degradation of the PEIJ-PLLA prostheses induced an 
optimal arterialization of the vein graft and that the 
arterialization process was more or less completed 
within 6 wk. The PEIJ-PC1 prostheses were fragmented 
a9 
less excessively than the PEU-PLLA prostheses after 
6 wk of implantation and most likely still supported 
the vein grafts to some extent”“. The vein grafts 
supported by the PEU-PC1 prostheses were not dilated 
but had also not reached the wall thickness of that of 
the adjacent artery. It is likely that after prolonged 
implantation times, during which the supporting 
function of the prosthesis decreases further, vein graft 
wall thickening without graft dilation will proceed 
until the arterialization process is completed. After 
6wk of implantation the PC1 prostheses did not show 
any macroscopical signs of degradation and most 
likely retained their initial mechanical strength. It is 
therefore likely that at this time the arterialization 
process had not yet finished. 
From these results it can be concluded that the 
degradation rate of the prostheses determines the 
arterialization rate of the vein grafts. However, since 
thickening of the vein graft wall is limited to a certain 
maximum rate, the degradation of the prostheses 
should also not exceed that rate to prevent graft 
dilation. 
Preferably, a foreign material should remain in the 
body only as long as it is required. In our animal 
model, the PEU-PLLA prostheses induced the best 
balance of rapid degradation and optimal arterializa- 
tion of the vein grafts. However, the degradation rate 
in a clinical situation might be different since the 
arterialization rate is likelv to be species 
dependent”“, “’ and is furthermore determined by the 
original thickness of the vein graft wall. Therefore, a 
series of prostheses differing in degradation rate 
should be available. 
In the present study we used two different PEIJ-based 
prostheses, the PEU-PLLA and PEIJ-PC1 prostheses, 
which lost their supporting function at different rates. 
In a previous study, in which these prostheses were 
used as vascular substitutes, it was shown that the 
prostheses fragment in viva by alternating stresses 
induced by arterial pulsationsZf’. Bv changing the 
composition of these prostheses, a series of prostheses 
with a broad range of fragmentation rates can he 
obtained”‘,““. Therefore, this series of prostheses 
seems ideal as supporting prostheses for vein grafts. 
However, care must he exercised to apply fragmentable 
prostheses based on polyurethanes in humans because 
it is not known how long it takes until the polymer 
fragments are degraded completely and whether 
degradation products accumulate in the body. 
Moreover, when polyurethanes in which the hard 
segments are based on aromatic diisocyanatos are 
used, highly toxic aromatic: diamines may he formed 
during degradation”“m44. 
Alternatives for blend prostheses are prostheses 
composed of biodegradable elastomeric copolymers 
which are built up from non-toxic naturally occurring 
metabolites and of which the degradation rate can he 
varied by changing the monomer ratio. The Cop 4.5 
and PC1 prostheses used in the present study belong to 
such a series of prostheses. It was found that the PC1 
prostheses degraded slowly. Qualitative inspections of 
the implant 6wk after implantation did not show any 
loss of integrity of the prostheses and even 6 months 
after implantation the prostheses still seemed 
Biomaterials 1994. Vol. 15 No. 2 
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relatively unaffected (data not shown).’ In contrast, the 
Cop 4.5 prostheses degraded very rapidly. After 3 wk 
of implantation only fragments of the material were 
left and after 6 wk of implantation the material had 
completely disappeared. These findings indicate that a 
series of prostheses with a very broad range of degrada- 
tion rates can be prepared by varying the c-caprolac- 
tone-morpholinedione ratio between %.5:,4.5 and 
100:O. Therefore, we recommend prostheses made of 
these copolymers to support the vein grafts. 
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